The Defense Advanced Research Projects Agency has launched an effort to develop new psychotherapeutic medicine for the mental health of servicemen and veterans.
DARPA said Wednesday its Focused Pharma program aims to address anxiety, depression, post-traumatic stress and other neuropsychiatric states.
The agency identified negative thought processes as a common factor in neuropsychiatric conditions that affect one’s functional abilities. Its program aims to foster the development of compounds that augment neurotransmission processes that usually impact the physiology of one’s brain.
Focused Pharma’s intended resultant drug will selectively target neurotransmission pathways associated with neuropsychiatric issues.
DARPA will host a proposer’s day on Oct. 1 to discuss program details with interested parties. Registration for the event is open through Sept. 24.